Hunan Tender Creates Industry Jitters In China
This article was originally published in PharmAsia News
The price slashes were so harsh that industry associations have staged a rare faceoff with authorities, with many worrying that the Hunan drug tender, being the first in the year, may herald a new round of drug price cuts in China.
You may also be interested in...
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.
An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.